Selection and dosing of medications for management of diabetes in patients with advanced kidney disease

Seminars in Dialysis

Volumn 23, Issue 2, 2010, Pages 163-168

  Reilly, James B ^a   Berns, Jeffrey S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; INSULIN; SULFONYLUREA DERIVATIVE; GLYCOSIDASE INHIBITOR;

ARTICLE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; DRUG ANTAGONISM; HUMAN; DIABETIC NEPHROPATHIES; KIDNEY FAILURE, CHRONIC;

ALPHA-GLUCOSIDASES; BIGUANIDES; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY FAILURE, CHRONIC; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; GLYCOSIDE HYDROLASE INHIBITORS;

EID: 77953207589     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00703.x     Document Type: Article

References (83)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
3. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
4. Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H, Shoji T, Nishizawa Y. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006, 29:1496-1500.
5. Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, Ishimura E, Nishizawa Y. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001, 24:909-913.
6. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia 1984, 27:351-357.
7. Rubenstein AH, Mako ME, Horwitz DL. Insulin and the kidney. Nephron 1975, 15:306-326.
8. Rave K, Heise T, Pfutzner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 2001, 24:886-890.
9. Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med 2003, 20:642-645.
10. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000, 13:4-8.
11. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000, 26(Suppl. 4):73-85.
12. Aronoff G, Berns JS, Brier ME, Kasbekar N, Mueller BA, Pasko DA, Smoyer WE. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children 2007, 5th edn, Philadelphia, American College of Physicians
13. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 2007, 50:865-879.
14. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002, 137:25-33.
15. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996, 334:574-579.
16. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996, 30:359-371.
17. Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996, 31:111-119.
18. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987, 23:545-551.
19. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998, 338:265-266.
20. Heupler FA. Guidelines for performing angiography in patients taking metformin. Members of the Laboratory Performance Standards Committee of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Diagn 1998, 43:121-123.
21. Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J. Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol 1989, 27:285-288.
22. Seidowsky A, Nseir S, Houdret N, Fourrier F. Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med 2009, 37:2191-2196.
23. Arroyo AM, Walroth TA, Mowry JB, Kao LW. The MALAdy of metformin poisoning: is CVVH the cure? Am J Ther
24. Bruijstens LA, van Luin M, Buscher-Jungerhans PM, Bosch FH. Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. Neth J Med 2008, 66:185-190.
25. Scheen AJ, Lefebvre PJ. Potential pharmacokinetics interference between alpha-glucosidase inhibitors and other oral antidiabetic agents. Diabetes Care 2002, 25:247-248.
26. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004, 17:365-370.
27. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989, 321:1231-1245.
28. Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J. Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 1973, 9(Suppl 1):331-338.
29. Feldman JM. Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects. Pharmacotherapy 1985, 5:43-62.
30. Pearson JG, Antal EJ, Raehl CL, Gorsch HK, Craig WA, Albert KS, Welling PG. Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther 1986, 39:318-324.
31. Brier ME, Bays H, Sloan R, Stalker DJ, Welshman I, Aronoff GR. Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure. Am J Kidney Dis 1997, 29:907-911.
32. Jonsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 1998, 53:429-435.
33. Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994, 17:1026-1030.
34. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000, 35:500-505.
35. Holstein A, Plaschke A, Hammer C, Egberts EH. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 2003, 59:91-97.
36. Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996, 39:1617-1624.
37. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2003, 111:405-414.
38. Iglesias P, Diez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 2006, 154:613-621.
39. Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompor T, Eckland D. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003, 55:368-374.
40. Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 2003, 43:252-259.
41. Thompson-Culkin K, Zussman B, Miller AK, Freed MI. Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. J Int Med Res 2002, 30:391-399.
42. Aramwit P, Supasyndh O, Sriboonruang T. Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients. J Clin Pharm Ther 2008, 33:685-690.
43. Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 2003, 115(Suppl. 8A):111S-115S.
44. Kiryluk K, Isom R. Thiazolidinediones and fluid retention. Kidney Int 2007, 72:762-768.
45. Vallon V, Hummler E, Rieg T, Pochynyuk O, Bugaj V, Schroth J, Dechenes G, Rossier B, Cunard R, Stockand J. Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity. J Am Soc Nephrol 2009, 20:721-729.
46. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005, 11:861-866.
47. Panchapakesan U, Pollock C, Saad S. Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake. Nephrology (Carlton) 2009, 14:298-301.
48. Staels B. Fluid retention mediated by renal PPARgamma. Cell Metab 2005, 2:77-78.
49. Rennings AJ, Smits P, Stewart MW, Tack CJ. Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes Care 2006, 29:581-587.
50. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998, 47:810-814.
51. Wong TY, Szeto CC, Chow KM, Leung CB, Lam CW, Li PK. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005, 46:713-719.
52. Manley HJ, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 2003, 23:861-865.
53. Chiang CK, Ho TI, Peng YS, Hsu SP, Pai MF, Yang SY, Hung KY, Wu KD. Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care 2007, 30:3-7.
54. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
55. Ramirez SP, Albert JM, Blayney MJ, Tentori F, Goodkin DA, Wolfe RA, Young EW, Bailie GR, Pisoni RL, Port FK. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009, 20:1094-1101.
56. Brunelli SM, Thadhani R, Ikizler TA, Feldman HI. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int 2009, 75:961-968.
57. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003, 108:2941-2948.
58. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001, 358:1709-1716.
59. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002, 41:471-483.
60. Marbury TC, Ruckle JL, Hatorp V, Andersen MP, Nielsen KK, Huang WC, Strange P. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000, 67:7-15.
61. Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, Hasslacher C. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 2001, 57:147-152.
62. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003, 26:886-891.
63. Weaver ML, Orwig BA, Rodriguez LC, Graham ED, Chin JA, Shapiro MJ, McLeod JF, Mangold JB. Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos 2001, 29:415-421.
64. Devineni D, Walter YH, Smith HT, Lee JS, Prasad P, McLeod JF. Pharmacokinetics of nateglinide in renally impaired diabetic patients. J Clin Pharmacol 2003, 43:163-170.
65. Inoue T, Shibahara N, Miyagawa K, Itahana R, Izumi M, Nakanishi T, Takamitsu Y. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003, 60:90-95.
66. Nagai T, Imamura M, Iizuka K, Mori M. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract 2003, 59:191-194.
67. Unger RH. Reinventing type 2 diabetes: pathogenesis, treatment, and prevention. JAMA 2008, 299:1185-1187.
68. Gromada J, Brock B, Schmitz O, Rorsman P. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol 2004, 95:252-262.
69. Gromada J, Rorsman P. New insights into the regulation of glucagon secretion by glucagon-like peptide-1. Horm Metab Res 2004, 36:822-829.
70. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 2009, 122:S37-S50.
71. Bray GM. Exenatide. Am J Health Syst Pharm 2006, 63:411-418.
72. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007, 64:317-327.
73. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 2006, 7:367-374.
74. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
75. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002, 25:1398-1404.
76. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005, 78:675-688.
77. Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007, 30:1862-1864.
78. Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008, 10:545-555.
79. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther 2009, 26:249-262.
80. Fura A, Khanna A, Vyas V, Koplowitz B, Chang SY, Caporuscio C, Boulton DW, Christopher LJ, Chadwick KD, Hamann LG, Humphreys WG, Kirby M. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 2009, 37:1164-1171.
81. http://packageinserts.bms.com/pi/pi_onglyza.pdf, Product package insert. Available at , accessed September 11, 2009
82. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009, 54:516-523.
83. Grouzmann E, Livio F, Buclin T. Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors. An increased risk of angioedema. Hypertension 2009, 54:468-470.